Cite
HARVARD Citation
Giné, E. et al. (2022). Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of clinical oncology. 40 (11), pp. 1196-1205. [Online].